As expected expression of CARMA1 L225LI leads to a significant upregulation of the NF-κB gene signature as exemplified by an ABC DLBCL or BCR signaling-derived NF-κB signature (Supplementary Figures S6a and b).3, 26 NF-κB signatures were significantly lower in CARMA1 WT, R35A or L225LI/R35A-expressing cells, revealing that the recruitment of BCL10 is essential for CARMA1-triggered NF-κB activation (Supplementary Figures S6b and c). The gene discussed is NFKB1; the disease is diffuse large B-cell lymphoma.